Biogen (BIIB) got FDA approval $ on their Alzheimer’s Drug yesterday . Seems like a good thing.
Biogen then named their price for year supply . 56,000$ , what a racket pricing in that industry is.
However when you read how they stopped their phase 3 trials due to emerge and engage missing endpoints in intern analysis , They removed it from their pipeline , only to decide in fall 2019 that if you look at the data sideways (Biogen decided to reinterpret the data and say it was better (lol) they reapplied to FDA , got shutdown twice bc the results were based on divergent data , and then Now were miraculously just approved under agency’s accelerated approval pathway . Sounds really solid ..... sad actually . Advisory panel urged a no vote as recent as April 2021.
https://www.alzforum.org/therapeutics/aducanumab
https://www.statnews.com/2021/05/30/if-the-fda-approves-biogens-alzheimers-treatment-i-wont-prescribe-it/